UCB

News

EULAR 26 hears of treatment advances in lupus

Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

R&D

12 Questions With Marie Teil

Marie Teil is a pharmaceutical executive with over 20 years of experience in the healthcare field. She leads UCB's Women of Childbearing Age programme

News

UCB buys T-cell therapy biotech Candid for $2bn upfront

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

News

NICE backs UCB drug as first uncontrolled gMG therapy

UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

EULAR 26 hears of treatment advances in lupus

Why UCB bet a billion dollars on cell therapy for epilepsy

12 Questions With Marie Teil

UCB buys T-cell therapy biotech Candid for $2bn upfront

NICE backs UCB drug as first uncontrolled gMG therapy

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

UCB

Editor's Picks